Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges

Larkin, 2019, Five-year survival with combined nivolumab and ipilimumab in advanced melanoma, N. Engl. J. Med., 381, 1535, 10.1056/NEJMoa1910836 Ascierto, 2020, Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial, Lancet Oncol., 21, 1465, 10.1016/S1470-2045(20)30494-0 Eggermont, 2020, Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial, J. Clin. Oncol., 38, 3925, 10.1200/JCO.20.02110 Eggermont, 2021, Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, Lancet Oncol., 22, 643, 10.1016/S1470-2045(21)00065-6 Sharma, 2017, Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707, 10.1016/j.cell.2017.01.017 Teng, 2015, Classifying cancers based on T-cell infiltration and PD-L1, Cancer Res., 75, 2139, 10.1158/0008-5472.CAN-15-0255 Cristescu, 2018, Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy, Science, 362, eaar3593, 10.1126/science.aar3593 Trujillo, 2018, T cell-Inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection, Cancer Immunol. Res., 6, 990, 10.1158/2326-6066.CIR-18-0277 Li, 2021, Targeting MDSC for immune-checkpoint blockade in cancer immunotherapy: current progress and new prospects, Clin. Med Insights Oncol., 15, 10.1177/11795549211035540 Indini, 2021, Metabolic interplay between the immune system and melanoma cells: therapeutic implications, Biomedicines, 9, 607, 10.3390/biomedicines9060607 Jiang, 2021, Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy, Front. Immunol., 11, 10.3389/fimmu.2020.622509 Gao, 2020, Integration of the tumor mutational burden and tumor heterogeneity identify an immunological subtype of melanoma with favorable survival, Front Oncol., 10, 10.3389/fonc.2020.571545 Daud, 2016, Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma, J. Clin. Investig., 126, 3447, 10.1172/JCI87324 Wang, 2020, Therapeutic strategies to remodel immunologically cold tumors, Clin. Transl. Immunol., 9, 10.1002/cti2.1226 Erdag, 2012, Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma, Cancer Res., 72, 1070, 10.1158/0008-5472.CAN-11-3218 Obeid, 2017, The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?, Melanoma Res., 27, 211, 10.1097/CMR.0000000000000330 Sobottka, 2021, Establishing standardized immune phenotyping of metastatic melanoma by digital pathology, Lab. Investig., 101, 1561, 10.1038/s41374-021-00653-y Giraldo, 2021, Spatial UMAP and image cytometry for topographic immuno-oncology biomarker discovery, Cancer Immunol. Res, 9, 1262, 10.1158/2326-6066.CIR-21-0015 Taube, 2020, The society for immunotherapy of cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation, 8 Akturk, 2021, Multiplex tissue imaging harmonization: a multicenter experience from CIMAC-CIDC immuno-oncology biomarkers network, Clin. Cancer Res., 27, 5072, 10.1158/1078-0432.CCR-21-2051 Nguyen, 2021, Multiplex immunohistochemistry analysis of melanoma tumor-infiltrating lymphocytes, Methods Mol. Biol., 2265, 557, 10.1007/978-1-0716-1205-7_39 Halse, 2018, Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma, Sci. Rep., 8, 11158, 10.1038/s41598-018-28944-3 Gide, 2019, Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients, Oncoimmunology, 9, 1659093, 10.1080/2162402X.2019.1659093 Gartrell, 2018, Quantitative analysis of immune infiltrates in primary melanoma, Cancer Immunol. Res., 6, 481, 10.1158/2326-6066.CIR-17-0360 Quek, 2021, High-dimensional single-cell transcriptomics in melanoma and cancer immunotherapy, Genes (Basel), 12, 1629, 10.3390/genes12101629 Khalili, 2012, Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma, Clin. Cancer Res., 18, 5329, 10.1158/1078-0432.CCR-12-1632 Liu, 2013, BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice, Clin. Cancer Res., 19, 393, 10.1158/1078-0432.CCR-12-1626 Bradley, 2015, BRAFV600E Co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma, Cancer Immunol. Res., 3, 602, 10.1158/2326-6066.CIR-15-0030 Jerby-Arnon, 2018, A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade, Cell, 175, 984, 10.1016/j.cell.2018.09.006 Galvani, 2020, Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma, Nat. Commun., 11, 853, 10.1038/s41467-020-14632-2 Bald, 2014, Lopez-Ramos D, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation, Cancer Disco, 4, 674, 10.1158/2159-8290.CD-13-0458 Leick, 2019, Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors, Cancer Immunol. Immunother., 68, 1121, 10.1007/s00262-019-02345-5 Sistigu, 2014, Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy, Nat. Med, 20, 1301, 10.1038/nm.3708 Chelvanambi, 2021, STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment, J. Immunother. Cancer, 9, 10.1136/jitc-2020-001906 Reilley, 2019, TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma, J. Immunother. Cancer, 7, 323, 10.1186/s40425-019-0811-x Ferrucci, 2021, Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma, Cancers (Basel), 13, 1383, 10.3390/cancers13061383 Uche, 2021, Novel oncolytic herpes simplex virus 1 VC2 promotes long-lasting, systemic anti-melanoma tumor immune responses and increased survival in an immunocompetent B16F10-derived mouse melanoma model, J. Virol., 95, 10.1128/JVI.01359-20 Ring, 2021, Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment, Nat. Commun., 12, 4734, 10.1038/s41467-021-25057-w Castro, 2018, Interferon-gamma at the crossroads of tumor immune surveillance or evasion, Front Immunol., 9, 847, 10.3389/fimmu.2018.00847 Ayers, 2017, IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade, J. Clin. Invest, 127, 2930, 10.1172/JCI91190 Liu, 2019, Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma, Nat. Med, 25, 1916, 10.1038/s41591-019-0654-5 Gao, 2016, Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to Anti-CTLA-4 therapy, Cell, 167, 397, 10.1016/j.cell.2016.08.069 Apriamashvili, 2022, Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling, Nat. Commun., 13, 1923, 10.1038/s41467-022-29442-x Pan, 2018, A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing, Science, 359, 770, 10.1126/science.aao1710 Manguso, 2017, In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target, Nature, 547, 413, 10.1038/nature23270 Zhou, 2021, Interferon-gamma signaling promotes melanoma progression and metastasis, bioRxiv Luo, 2018, Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2, Oncoimmunology, 7, 10.1080/2162402X.2018.1438106 Glodde, 2017, Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy, Immunity, 47, 789, 10.1016/j.immuni.2017.09.012 Effern, 2020, Adoptive T cell therapy targeting different gene products reveals diverse and context-dependent immune evasion in melanoma, Immunity, 53, 564, 10.1016/j.immuni.2020.07.007 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Weng, 2018, Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis, Onco Targets Ther., 11, 7529, 10.2147/OTT.S167865 Oh, 2020, PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer, Nat. Cancer, 1, 681, 10.1038/s43018-020-0075-x Placke, 2021, Digital quantification of tumor PD-L1 predicts outcome of PD-1-based immune checkpoint therapy in metastatic melanoma, Front. Oncol., 11, 10.3389/fonc.2021.741993 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med, 372, 320, 10.1056/NEJMoa1412082 Samanta, 2015, Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity, Cell Mol. Life Sci., 72, 645, 10.1007/s00018-014-1763-4 Jin, 2021, Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy, BMB Rep., 54, 2, 10.5483/BMBRep.2021.54.1.229 Alteber, 2021, Therapeutic targeting of checkpoint receptors within the DNAM1 axis, Cancer Discov., 11, 1040, 10.1158/2159-8290.CD-20-1248 Chauvin, 2020, TIGIT in cancer immunotherapy, J. Immunother. Cancer, 8, 10.1136/jitc-2020-000957 Johnston, 2021, Cancer immunotherapy and the nectin family, 5, 203 Braun, 2020, CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells, Immunity, 53, 805, 10.1016/j.immuni.2020.09.010 Weulersse, 2020, Eomes-dependent loss of the Co-activating receptor CD226 Restrains CD8+ T cell anti-tumor functions and limits the efficacy of cancer immunotherapy, Immunity, 53, 824, 10.1016/j.immuni.2020.09.006 Jin, 2020, CD226hiCD8+ T cells are a prerequisite for Anti-TIGIT immunotherapyr, Cancer Immunol. Res., 8, 912, 10.1158/2326-6066.CIR-19-0877 Alteber, 2021, Therapeutic targeting of checkpoint receptors within the DNAM1 axis, Cancer Discov., 11, 1040, 10.1158/2159-8290.CD-20-1248 Mecham, 1989, Elastin binds to a multifunctional 67-kilodalton peripheral membrane protein, Biochemistry, 28, 3716, 10.1021/bi00435a014 Joller, 2014, Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses, Immunity, 40, 569, 10.1016/j.immuni.2014.02.012 Li, 2014, T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling, J. Biol. Chem., 289, 17647, 10.1074/jbc.M114.572420 Banta, 2022, Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitate co-blockade to optimize anti-tumor CD8+ T cell responses, Immunity, 55, 512, 10.1016/j.immuni.2022.02.005 Iguchi-Manaka, 2008, Accelerated tumor growth in mice deficient in DNAM-1 receptor, J. Exp. Med, 205, 2959, 10.1084/jem.20081611 Chan, 2010, DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases, J. Immunol., 184, 902, 10.4049/jimmunol.0903225 Zhang, 2015, DNAM-1 controls NK cell activation via an ITT-like motif, J. Exp. Med, 212, 2165, 10.1084/jem.20150792 Weulersse, 2020, Eomes-dependent loss of the co-activating receptor CD226 restrains CD8+ T cell anti-tumor functions and limits the efficacy of cancer immunotherapy, Immunity, 53, 824, 10.1016/j.immuni.2020.09.006 Chiang, 2022, TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy, J. Immunother. Cancer, 10, 10.1136/jitc-2022-004711 Passarelli, 2019, The metabolic milieu in melanoma: role of immune suppression by CD73/adenosine, Tumour Biol., 42 Allard, 2019, Targeting the CD73-adenosine axis in immuno-oncology, Immunol. Lett., 205, 31, 10.1016/j.imlet.2018.05.001 Allard, 2014, Anti-CD73 therapy impairs tumor angiogenesis, Int J. Cancer, 134, 1466, 10.1002/ijc.28456 Young, 2017, Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis, Cancer Res, 77, 4684, 10.1158/0008-5472.CAN-17-0393 Yan, 2020, Control of metastases via myeloid CD39 and NK cell effector function, Cancer Immunol. Res., 8, 356, 10.1158/2326-6066.CIR-19-0749 Li, 2019, Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity, Cancer Disco, 9, 1754, 10.1158/2159-8290.CD-19-0541 Perrot, 2019, Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies, Cell Rep., 27, 2411, 10.1016/j.celrep.2019.04.091 Allard, 2013, Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs, Clin. Cancer Res., 19, 5626, 10.1158/1078-0432.CCR-13-0545 Reinhardt, 2017, MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy, Cancer Res., 77, 4697, 10.1158/0008-5472.CAN-17-0395 Turiello, 2022, Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents, J. Immunother. Cancer, 10, 10.1136/jitc-2021-004043 Turiello, 2020, Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy, J. Immunother. Cancer, 8, 10.1136/jitc-2020-001689 Wing, 2008, CTLA-4 control over Foxp3+ regulatory T cell function, Science, 322, 271, 10.1126/science.1160062 Sakuishi, 2013, TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer, Oncoimmunology, 2, 10.4161/onci.23849 Fourcade, 2018, CD226 opposes TIGIT to disrupt Tregs in melanoma, JCI Insight, 3, 10.1172/jci.insight.121157 Huang, 2021, Targeting regulatory T cells for immunotherapy in melanoma, Mol. Biomed., 2, 11, 10.1186/s43556-021-00038-z Fridlender, 2009, Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN, Cancer Cell, 16, 183, 10.1016/j.ccr.2009.06.017 Finisguerra, 2015, MET is required for the recruitment of anti-tumoural neutrophils, Nature, 522, 349, 10.1038/nature14407 Bald, 2014, Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma, Nature, 507, 109, 10.1038/nature13111 Glodde, 2017, Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy, Immunity, 47, 789, 10.1016/j.immuni.2017.09.012 Faget, 2021, Neutrophils in the era of immune checkpoint blockade, J. Immunother. Cancer, 9, 10.1136/jitc-2020-002242 Singh, 2021, IL-1α mediates innate and acquired resistance to immunotherapy in melanoma, J. Immunol., 206, 1966, 10.4049/jimmunol.2000523 Daoud, 2022, XIAP promotes melanoma growth by inducing tumour neutrophil infiltration, EMBO Rep., 10.15252/embr.202153608 Fujimura, 2018, Front Oncol., 8, 3, 10.3389/fonc.2018.00003 Modak, 2022, CD206+ tumor-associated macrophages cross-present tumor antigen and drive anti-tumor immunity, JCI Insight, 10.1172/jci.insight.155022 Zeng, 2022, Melanoma and nanotechnology-based treatment, Front Oncol., 12 Guan, 2021, Recent progress in nanomedicine for melanoma theranostics with emphasis on combination therapy, Front Bioeng. Biotechnol., 9, 10.3389/fbioe.2021.661214 Chiang, 2018, Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy, Nat. Nanotechnol., 13, 746, 10.1038/s41565-018-0146-7 Zhu, 2020, Albumin-biomineralized nanoparticles to synergize phototherapy and immunotherapy against melanoma, J. Control Release, 322, 300, 10.1016/j.jconrel.2020.03.045 Zou, 2019, Cyclic RGD-functionalized and disulfide-crosslinked iodine-rich polymersomes as a robust and smart theranostic agent for targeted CT imaging and chemotherapy of tumor, Theranostics, 9, 8061, 10.7150/thno.37184 Massi, 2014, PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics, Ann. Oncol., 25, 2433, 10.1093/annonc/mdu452 Abd Hamid, 2020, Self-maintaining CD103+ cancer-specific T cells are highly energetic with rapid cytotoxic and effector responses, Cancer Immunol. Res., 8, 203, 10.1158/2326-6066.CIR-19-0554 Edwards, 2018, CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naïve melanoma patients and expand significantly during Anti-PD-1 treatment, Clin. Cancer Res., 24, 3036, 10.1158/1078-0432.CCR-17-2257 Mandalà, 2017, Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation, Lab Invest, 97, 166, 10.1038/labinvest.2016.132 Lepletier, 2020, Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma, Clin. Cancer Res, 26, 3671, 10.1158/1078-0432.CCR-19-3925 Gide, 2019, Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients, Oncoimmunology, 9, 1659093, 10.1080/2162402X.2019.1659093 Gartrell, 2018, Quantitative analysis of immune infiltrates in primary melanoma, Cancer Immunol. Res., 6, 481, 10.1158/2326-6066.CIR-17-0360 Messina, 2012, 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?, Sci. Rep., 2, 765, 10.1038/srep00765 Cabrita, 2020, Tertiary lymphoid structures improve immunotherapy and survival in melanoma, Nature, 577, 561, 10.1038/s41586-019-1914-8 Gide, 2019, Distinct immune cell populations define response to Anti-PD-1 monotherapy and anti-PD-1/Anti-CTLA-4 combined therapy, Cancer Cell, 35, 238, 10.1016/j.ccell.2019.01.003 Lauss, 2017, Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma, Nat. Commun., 8, 1738, 10.1038/s41467-017-01460-0 Van Allen, 2015, Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, 350, 207, 10.1126/science.aad0095 Hugo, 2016, Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma, Cell, 165, 35, 10.1016/j.cell.2016.02.065 Cui, 2021, Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma, NPJ Genom. Med., 6, 7, 10.1038/s41525-021-00169-w Jiang, 2018, Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response, Nat. Med., 24, 1550, 10.1038/s41591-018-0136-1 Ott, 2019, T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028, J. Clin. Oncol., 37, 318, 10.1200/JCO.2018.78.2276 Newell, 2022, Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance, Cancer Cell., 40, 88, 10.1016/j.ccell.2021.11.012 Blank, 2018, Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma, Nat. Med, 24, 1655, 10.1038/s41591-018-0198-0 Rozeman, 2019, Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicenter, phase 2, randomized, controlled trial, Lancet Oncol., 20, 948, 10.1016/S1470-2045(19)30151-2 Rozeman, 2021, Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma, Nat. Med, 27, 256, 10.1038/s41591-020-01211-7 Reijers, 2020, Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: the DONIMI study, J. Clin. Oncol., 38, 10.1200/JCO.2020.38.15_suppl.TPS10087 Blank, 2021, Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): the DONIMI study, Ann. Oncol., 32, S1283 Ayers, 2017, IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade, J. Clin. Investig., 127, 2930, 10.1172/JCI91190 Versluis, 2021, The prognostic value of the interferon-gamma (IFNγ) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy, J. Clin. Oncol., 39, 10.1200/JCO.2021.39.15_suppl.9579 Long, 2018, Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib (D) + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma, Ann. Oncol., 29, VIII734, 10.1093/annonc/mdy424.053 Huang, 2017, T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, 545, 60, 10.1038/nature22079 Goltz, 2018, CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients, JCI Insight, 3, 10.1172/jci.insight.96793 Jung, 2019, DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load, Nat. Commun., 10, 4278, 10.1038/s41467-019-12159-9 Kim, 2021, Melanoma dedifferentiation induced by IFN-γ epigenetic remodelling in response to anti-PD-1 therapy, J. Clin. Invest., M 131 Galon, 2019, Approaches to treat immune hot, altered and cold tumours with combination immunotherapies, Nat. Rev. Drug Discov., 18, 197, 10.1038/s41573-018-0007-y Tawbi, 2022, Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma, N. Engl. J. Med., 386, 24, 10.1056/NEJMoa2109970 Du, 2017, TIM-3 as a target for cancer immunotherapy and mechanisms of action, Int J. Mol. Sci., 18, 645, 10.3390/ijms18030645 Manieri, 2017, TIGIT: a key inhibitor of the cancer immunity cycle, Trends Immunol., 38, 20, 10.1016/j.it.2016.10.002 Gao, 2017, VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer, Nat. Med, 23, 551, 10.1038/nm.4308 Buchan, 2018, The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy, Blood, 131, 39, 10.1182/blood-2017-07-741025 Esensten, 2016, CD28 costimulation: from mechanism to therapy, Immunity, 44, 973, 10.1016/j.immuni.2016.04.020 Harvey, 2015, Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics, J. Immunother. Cancer, 3, O9, 10.1186/2051-1426-3-S2-O9 Maio, 2021, Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC), AACR J., 81 Peng, 2015, Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy, Nature, 527, 249, 10.1038/nature15520 Tang, 2016, Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade, Cancer Cell., 29, 285, 10.1016/j.ccell.2016.02.004 Hurkmans, 2020, Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma, J. Immunother. Cancer, 8, 10.1136/jitc-2020-001193 Arance, 2021, Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004, J. Clin. Oncol., 39, 10.1200/JCO.2021.39.15_suppl.9504 Leone, 2018, Targeting adenosine for cancer immunotherapy, J. Immunother. Cancer, 6, 57, 10.1186/s40425-018-0360-8 Diab, 2021, Bempegaldesleukin plus nivolumab in first-line metastatic melanoma, J. Clin. Oncol., 39, 2914, 10.1200/JCO.21.00675 Mehmi, 2021, Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma, J. Clin. Oncol., 39, 10.1200/JCO.2021.39.15_suppl.TPS9589 Long, 2019, Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study, Lancet Oncol., 20, 1083, 10.1016/S1470-2045(19)30274-8 Ribas, 2021, Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma, Cancer Discov., 10.1158/2159-8290.CD-21-0425 Chelvanambi, 2021, STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment, J. Immunother. Cancer, 9, 10.1136/jitc-2020-001906 Moore, 2016, Established T cell-inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade, Cancer Immunol. Res, 4, 1061, 10.1158/2326-6066.CIR-16-0104 Whiteside, 2016, Emerging opportunities and challenges in cancer immunotherapy, Clin. Cancer Res., 22, 1845, 10.1158/1078-0432.CCR-16-0049 Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu Rev. Immunol., 31, 51, 10.1146/annurev-immunol-032712-100008 Kaufman, 2015, Oncolytic viruses: a new class of immunotherapy drugs, Nat. Rev. Drug Discov., 14, 642, 10.1038/nrd4663 Gogas, 2021, MASTERKEY-265: a phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL), Ann. Oncol., 32, S867